Evaluating Mucilage from Aloe Barbadensis Miller as a Pharmaceutical Excipient for Sustained-Release Matrix Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Evaluating Mucilage from Aloe Barbadensis Miller as a Pharmaceutical Excipient for Sustained-Release Matrix Tablets
Natural gums and mucilage have been widely explored as pharmaceutical excipients. The goal of this study was to extract mucilage from the leaves of Aloe barbadensis Miller and to study its functionality as an excipient in pharmaceutical sustained-release tablet formulations.


Pharmaceutical Technology


Results and discussion


Table II: Physicochemical and microbial properties of dried powdered mucilage.
Various physiochemical and microbial characteristics of the extracted mucilage from A. barbadensis were investigated. The presence of mucilage in extracted material was confirmed using Molisch's test and by treatment with ruthenium red. Both tests were positive for the presence of mucilage. The results of other investigations (percentage yield, particle size, pH of solution, density, and charring) are shown in Table II. The weight loss on drying indicates the amount of moisture present in the material available to interact with other material. For dried mucilage, the loss on drying was 4.89%. The result of microbial testing of the mucilage was within official limits [less than 100 colony-forming units (cfg)/g]. The swelling ratio of mucilage, determined in distilled water, was 40. There was a significant change in swelling by the end of the study, which indicated that the mucilage had excellent swelling properties.


Table III: Rheological data of Aloe barbadensis mucilage and sodium carboxymethylcellulose (CMC).
The viscosity of the extracted dried mucilage was compared with a semisynthetic polymer (sodium CMC). The range of viscosities over the concentration range studied was 5.03 to 9.96 mPa s for dried mucilage and 2.79 to 12.15 mPa s for sodium CMC (see Table III). It can be concluded that the dried mucilage has viscosity comparable with sodium CMC.


Table IV: Flow properties of dried Aloe barbadensis mucilage and other gums.
The flow properties and compressibility of the dried mucilage, including bulk and tapped density, Carr's index, the Hausner ratio, and the angle of repose, were assessed. Comparison was made with guar gum and ispaghula, two other natural materials (see Table IV). The dried mucilage has excellent flow properties compared with guar gum and ispaghula. It can be concluded that the dried mucilage has flow properties suitable for a direct-compression formulation.

The physical tests (hardness test, friability, and weight variation) were performed for all formulations. Mean hardness for all formulations was about 4 kg/cm2 , friability was less than 1%, and the weight-variation results for the matrix tablets complied with pharmacopeial limits. From this work, it was shown that dried mucilage possesses good tablet-forming properties.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here